AbbVie Takes On Pfizer And Merck With Its Next Leg Of Growth. Will AbbVie Stock Come Back?

Blockhead12-17

AbbVie (ABBV) has a lofty goal for 2025 — and it could stoke the beleaguered AbbVie stock. The immunology powerhouse known for big-name drugs like Humira and Skyrizi, is eyeing expanding its reach in ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2492995090?lang=en_US&edition=fundamental","thumbnail":"https://www.investors.com/wp-content/uploads/2018/06/stock-AbbVie-04-company-150x150.jpg","is_english":true,"pubTime":"2024-12-17 21:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2492995090","market":"fut","top_or_hot":-1,"title":"AbbVie Takes On Pfizer And Merck With Its Next Leg Of Growth. Will AbbVie Stock Come Back?","media":"Blockhead","content":"<div>\n<p>AbbVie (ABBV) has a lofty goal for 2025 — and it could stoke the beleaguered AbbVie stock.\nThe immunology powerhouse known for big-name drugs like Humira and Skyrizi, is eyeing expanding its reach in ...</p>\n\n<a href=\"https://www.investors.com/news/technology/abbvie-stock-adcs-elahere-non-small-cell-lung-cancer/\">Source Link</a>\n\n</div>\n","source":"investor_business_daily_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AbbVie Takes On Pfizer And Merck With Its Next Leg Of Growth. Will AbbVie Stock Come Back?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAbbVie Takes On Pfizer And Merck With Its Next Leg Of Growth. Will AbbVie Stock Come Back?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-17 21:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.investors.com/news/technology/abbvie-stock-adcs-elahere-non-small-cell-lung-cancer/><strong>Blockhead</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AbbVie (ABBV) has a lofty goal for 2025 — and it could stoke the beleaguered AbbVie stock.\nThe immunology powerhouse known for big-name drugs like Humira and Skyrizi, is eyeing expanding its reach in ...</p>\n\n<a href=\"https://www.investors.com/news/technology/abbvie-stock-adcs-elahere-non-small-cell-lung-cancer/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2237443382.USD","symbol_name":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA USD","start_time":0,"source_url":"https://www.investors.com/news/technology/abbvie-stock-adcs-elahere-non-small-cell-lung-cancer/","article_id":"2492995090","we_media_id":null,"thumbnails":["https://www.investors.com/wp-content/uploads/2018/06/stock-AbbVie-04-company-150x150.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2492995090","pubTimestamp":1734440445,"columns":[],"sourceInfo":{"source_id":"investor_business_daily_highlight","name":"Investor’s Business Daily"},"weMediaInfo":null,"summary":"AbbVie has a lofty goal for 2025 — and a big move in cancer treatment could stoke beleaguered AbbVie stock.","collect":0,"end_time":0,"defaultTopTitle":"investors.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2237443382.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA USD","LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","IE00BN8TJ469.HKD":"FTGF CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A\" (HKD) INC","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","LU0310800379.SGD":"FTIF - Templeton Global A Acc SGD","BK4007":"制药","GSK.UK":"葛兰素史克","PFE.AU":"PANTERA MINERALS LTD","NVO":"诺和诺德","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","SG9999002232.USD":"Allianz Global High Payout USD","PFE":"辉瑞","LU1941712264.USD":"ALLIANZ PET AND ANIMAL WELLBEING \"A\" (USD) INC","MRK":"默沙东","LU0310799852.SGD":"FTIF - Templeton Global Equity Income A MDIS SGD","LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF","LU0058720904.USD":"联博国际健康护理基金A","LU0661504455.SGD":"Blackrock Global Equity Income A5 SGD-H","BK4568":"美国抗疫概念","BK4588":"碎股","LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV","LU2347655156.SGD":"JPMorgan Investment Funds - Global Income A (icdiv) SGD-H","LU2361044865.SGD":"WELLINGTON US QUALITY GROWTH \"A\" (SGDHDG) ACC","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","LU1267930573.SGD":"TEMPLETON GLOBAL \"AA\" (SGD) ACC A","LU0912757837.SGD":"JPMorgan Investment Funds - Global Income A (mth) SGD-H","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","LU0122379950.USD":"贝莱德世界健康科学A2","LU1244550221.USD":"FRANKLIN GLOBAL MULTI-ASSET  INCOME \"A\" (USDHEDGED) INC (M)","IE00BGHQF631.EUR":"GUINNESS GLOBAL EQUITY INCOME \"C\" (EUR) ACC","NVO.AU":"NOVO RESOURCES CORP-CDI","LU1267930490.SGD":"TEMPLETON GLOBAL EQUITY INCOME \"AS\" (SGD) INC A","IE00B3PB1722.GBP":"GUINNESS GLOBAL EQUITY INCOME \"C\" (GBP) INC","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU0708994859.HKD":"TEMPLETON GLOBAL \"A\" (HKD) ACC","LU0738911758.USD":"Blackrock Global Equity Income A6 USD","SG9999014542.SGD":"United Income Focus Trust Acc SGD","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","IE00B42XCP33.USD":"GUINNESS GLOBAL EQUITY INCOME \"C\" (USD) INC","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","ABBV":"艾伯维公司","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU1917777945.USD":"安联专题基金Cl AT Acc","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","GSK":"葛兰素史克","BK4592":"伊斯兰概念","LU0238689110.USD":"贝莱德环球动力股票基金","LU0265550946.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A5\" (USD) INC","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD"},"translate_title":"艾伯维(AbbVie)的下一阶段增长将挑战辉瑞(Pfizer)和默克(Merck)。艾伯维股票会回来吗？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABBV":1,"PFE.AU":1,"GSK":1,"PFE":1,"NVO.AU":1,"NVO":1,"MRK":1,"GSK.UK":0.6},"content_text":"AbbVie (ABBV) has a lofty goal for 2025 — and it could stoke the beleaguered AbbVie stock.\nThe immunology powerhouse known for big-name drugs like Humira and Skyrizi, is eyeing expanding its reach in cancer treatments. Last year, AbbVie's three immunology drugs accounted for nearly 49% of the company's total sales. In 2025, AbbVie hopes to grow its cancer portfolio markedly with the approval of the first solid-tumor cancer drug it developed in house.\n\n\n\n↑\nX\n\n\n\n\nHow To Buy Stocks: Trading Around A Core Position\n\n\nSee All Videos\n\n\n\n\nNOW PLAYING\nHow To Buy Stocks: Trading Around A Core Position\n\n\n\n\nThat drug, telisotuzumab vedotin, or Teliso-V for short, is an antibody drug conjugate. Think of these like smart bombs for cancer. They send toxic chemicals directly to targets that show up on tumor cells, limiting the damage to nearby healthy tissue.\nAbbVie isn't alone in the space. Battle lines are being drawn by high-profile rivals eager to take a chunk of the estimated $19.8 billion market by 2028, according to researchers from MarketsandMarkets. Pfizer (PFE) spent $43 billion last year to acquire ADC-maker Seagen. Merck (MRK) is paying Japan's Daiichi Sankyo up to $5.5 billion to jointly develop several ADCs. GSK (GSK) is nearing approval in small-cell lung cancer.\nTheir goal isn't small.\n\"Our goal is to replace chemotherapy,\" Pedro Valencia, AbbVie's vice president of solid tumor pipeline strategy and execution, told Investor's Business Daily. \"Instead of giving big, big doses of mild poison. We give little doses of really toxic poison. But it's the same poison. It's the same mechanism of action.\"\nAbbVie Stock: Expanding In Solid Tumors\nA small handful of ADCs have gained Food and Drug Administration approval. That includes Elahere, an approved ADC AbbVie acquired with ImmunoGen for $10.1 billion. Elahere treats ovarian, fallopian tube and peritoneal cancer by targeting the folate receptor alpha that shows up on those tumor cells.\nThis year, Elahere is expected to generate $471 million in sales for AbbVie, according to FactSet. In 2025, that could grow more than 49% to $703 million. Teliso-V is expected to notch its first sales next year with $38 million growing to $150 million in 2026 and $300 million in 2027.\nAbbVie has a handful of ADCs that came from its acquisition of ImmunoGen, including treatments for colon and lung cancers. But Teliso-V could mark an important milestone for AbbVie. If approved, it would be the first homegrown AbbVie drug developed by the company's own researchers that treats a solid-tumor cancer. The FDA is considering it as a treatment for non small-cell lung cancer (NSCLC).\nAbbVie's solid-tumor pipeline is a decade old. It's taken that long to near approval, says Valencia, because developing ADCs is tricky. First, researchers have to find a target — usually a protein — that shows up on tumor cells but not broadly elsewhere in the body. Then, they have to come up with a way to link the toxic payload to the antibody that locks onto the target.\n\"You're threading the needle here,\" he said. \"You want to get a linker that is as stable — meaning it's not just shedding off toxic payload — but is not so stable that it's not releasing the cargo. It tends to be almost an engineering optimization effort where you think about, 'OK, what is the best antibody, the best linker and the best payload?' That balance is not easy.\"\nBut once you figure it out, it's a repeatable process, he says.\n85% Of Lung Cancer Patients\nNon small-cell lung cancer, where Teliso-V is being developed, is a massive market. About 85% of lung cancer cases are NSCLC.\nTowards Healthcare, a market researcher, estimates this portion of the lung cancer market will grow to $21.5 billion by the end of 2033. Other estimates are even bigger, ranging from $36.9 billion by 2031 to $59.8 billion by 2030.\nAbbVie's other experimental ADCs come from its takeover of ImmunoGen. They include a treatment for the 15% of patients with small-cell lung cancer, or SCLC, and metastatic colorectal cancer. Both studies involved patients with \"no other options,\" Valencia said. Ultimately, 60% of patients with SCLC showed tumor shrinkage, and 40% of colon cancer patients reached the same bar.\nThe company is also working to move Elahere earlier into the treatment paradigm. Elahere is approved for patients who've undergone at least one previous treatment. But AbbVie hopes to eventually gain approval for Elahere in previously untreated ovarian cancer patients.\n\"We gave it to patients who've had two to three prior treatments and no more options,\" Valencia said of the SCLC treatment. \"Sixty percent of those patients had high tumor shrinkage. Every single patient had some sort of benefit. They have no other treatments, and we're giving them more life.\"\nAbbVie Stock Is Struggling\nAbbVie stock remains under pressure, however.\nShares slumped almost 13% on Nov. 11 after the company's experimental schizophrenia treatment failed in two midstage studies. The stock still hasn't recovered.\nToday, AbbVie stock trades below its 50-day and 200-day moving averages, according to MarketSurge. Coming up against those ceilings could prove to be a challenge.\nShares also have a low IBD Digital Relative Strength Rating of 30, meaning AbbVie stock trades in the lowest one-third of all stocks when it comes to 12-month performance. Still, AbbVie is one of the biggest drugmakers. In terms of market cap, it ranks second behind Novo Nordisk (NVO) in the Medical-Ethical Drugs industry group.\n\nFollow Allison Gatlin on X, the platform formerly known as Twitter, at @IBD_AGatlin.\nYOU MAY ALSO LIKE:\nViridian Stock Flashes A Bullish Sign In Its Eye-Disease Battle With Amgen\nBattle Over Weight-Loss Drugs: Can Eli Lilly, Novo Nordisk Defend Their Turf?\nLooking For The Next Big Stock Market Winners? Start With These 3 Steps\nShort-Term Trades Can Add Up To Big Profits. IBD's SwingTrader Shows You How\nFind Today's Best Growth Stocks To Watch With IBD 50","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2492995090"}